EUR 0.0
(0.0%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 543 Thousand EUR | 50.0% |
2022 | 206 Thousand EUR | -79.13% |
2021 | 987 Thousand EUR | -1.3% |
2020 | 1 Million EUR | 538.6% |
2019 | -228 Thousand EUR | -122.8% |
2018 | 1 Million EUR | 307.9% |
2017 | -481 Thousand EUR | 9.93% |
2016 | -534 Thousand EUR | -36.22% |
2015 | -392 Thousand EUR | 0.0% |
2014 | - EUR | 0.0% |
2013 | - EUR | 0.0% |
2012 | - EUR | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 1.24 Million EUR | 0.0% |
2024 Q1 | 1.34 Million EUR | 3161.36% |
2023 FY | 309 Thousand EUR | 50.0% |
2023 Q1 | 182.5 Thousand EUR | 158.87% |
2023 Q2 | 81.5 Thousand EUR | -55.34% |
2023 Q3 | 89 Thousand EUR | 9.2% |
2023 Q4 | -44 Thousand EUR | -149.44% |
2022 Q4 | 70.5 Thousand EUR | 0.0% |
2022 FY | 206 Thousand EUR | -79.13% |
2022 Q3 | 70.5 Thousand EUR | 161.84% |
2022 Q2 | -114 Thousand EUR | 0.0% |
2021 Q4 | 930 Thousand EUR | 0.0% |
2021 FY | 987 Thousand EUR | -1.3% |
2021 Q2 | -64 Thousand EUR | 0.0% |
2020 Q4 | 1 Million EUR | 0.0% |
2020 FY | 1 Million EUR | 538.6% |
2020 Q2 | -351 Thousand EUR | 0.0% |
2019 FY | -228 Thousand EUR | -122.8% |
2019 Q2 | -389 Thousand EUR | 0.0% |
2019 Q4 | -363 Thousand EUR | 0.0% |
2018 Q4 | 1 Million EUR | 0.0% |
2018 FY | 1 Million EUR | 307.9% |
2017 FY | -481 Thousand EUR | 9.93% |
2016 FY | -534 Thousand EUR | -36.22% |
2015 FY | -392 Thousand EUR | 0.0% |
2014 Q3 | - EUR | 0.0% |
2014 FY | - EUR | 0.0% |
2014 Q4 | - EUR | 0.0% |
2013 Q4 | - EUR | 0.0% |
2013 FY | - EUR | 0.0% |
2012 FY | - EUR | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Nicox S.A. | -11.5 Million EUR | 104.721% |
European Medical Solutions | 13.51 Million EUR | 95.981% |
FERMENTALG | 535 Thousand EUR | -1.495% |
argenx SE | 925.49 Million EUR | 99.941% |
Celyad Oncology SA | 33 Thousand EUR | -1545.455% |
Hyloris Pharmaceuticals SA | 1.99 Million EUR | 72.768% |
Onward Medical N.V. | -14.81 Million EUR | 103.664% |
Oxurion NV | 104 Thousand EUR | -422.115% |
PHAXIAM Therapeutics S.A. | 1.32 Million EUR | 59.05% |
Financière de Tubize SA | -2.02 Million EUR | 126.754% |
UCB SA | 3.34 Billion EUR | 99.984% |